IO Biotech Reports First Quarter 2025 Financial Results and Business Highlights
Written by Emily J. Thompson, Senior Investment Analyst
Updated: May 14 2025
0mins
Source: Newsfilter
Clinical Trial Progress: IO Biotech's pivotal Phase 3 trial for its cancer vaccine Cylembio® is on track, with primary endpoint results expected in Q3 2025. The company aims to submit a Biologics License Application (BLA) to the FDA later this year and plans to launch the vaccine in 2026 if approved.
Financial Performance and Recognition: In Q1 2025, IO Biotech reported a net loss of $22.4 million and was recognized by Fast Company as one of the world's most innovative biotechnology companies, ranking 9th in the sector.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy IOBT?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on IOBT
Wall Street analysts forecast IOBT stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for IOBT is 1.68 USD with a low forecast of 0.36 USD and a high forecast of 3.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
3 Analyst Rating
1 Buy
1 Hold
1 Sell
Hold
Current: 0.316
Low
0.36
Averages
1.68
High
3.00
Current: 0.316
Low
0.36
Averages
1.68
High
3.00
About IOBT
IO Biotech Inc is a clinical-stage biopharmaceutical company developing immune-modulating cancer therapies based on T-win technology platform. The Company’s product candidates are designed to induce the immune system to simultaneously target and disrupt multiple pathways that regulate tumor-induced immunosuppression. IO Biotech’s lead product candidate, IO102-IO103, is designed to target the immunosuppressive mechanisms mediated by key immunosuppressive proteins such as IDO and PD-L1. The Company develops a pipeline of product candidates that leverage its T-win technology platform to address targets within the TME. The Company is spin-off of National Cancer for Center Immune Therapy at Herlev University Hospital in Denmark.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
IO Biotech Engages Raymond James as Financial Advisor Amid Workforce Reduction
- Strategic Advisor Appointment: IO Biotech has engaged Raymond James & Associates as its exclusive financial advisor to assist in exploring strategic alternatives, indicating the company's commitment to business transformation and resource optimization.
- Workforce Reduction Implementation: The company is implementing significant layoffs to reduce operating expenses, a move aimed at ensuring financial stability and extending cash runway while exploring strategic options.
- Innovative Platform Background: IO Biotech focuses on developing immune-modulatory cancer vaccines based on its T-win® platform, designed to activate T cells to target both tumor cells and immune-suppressive cells, showcasing its technological potential in the biopharmaceutical sector.
- Market Outlook Uncertainty: While the company explores strategic alternatives, forward-looking statements highlight that its future financial position and cash runway may be affected by various risks and uncertainties, urging investors to approach the company's future performance with caution.
Continue Reading
Piper Sandler Downgrades IO Biotech to Neutral Amid Strategic Review
- Rating Downgrade: Piper Sandler downgraded IO Biotech from Overweight to Neutral, slashing the price target from $3 to $0.50, reflecting a cautious stance on the company's strategic opportunity exploration.
- Capital Constraints: While the underlying science of IO's T-win platform and lead candidate cylembio is promising, analysts highlight that the company faces capital constraints that could hinder future growth.
- Strategic Uncertainty: Piper's analysts indicate that there is no assurance that IO Biotech's strategic alternatives process will yield favorable outcomes or that any transactions will be completed on attractive terms, necessitating investor vigilance.
- Market Reaction: This downgrade may lead to diminished investor confidence in IO Biotech, further impacting its stock performance, particularly as the company seeks to maximize shareholder value amidst these challenges.
Continue Reading